Nitric oxide (NO) is a smooth-muscle relaxant synthesised by endothelium, and is capable of both systemic and pulmonary vasodilatation. In animal studies, inhaled NO produces pulmonary vasodilatation by direct action on pulmonary vasculature. I This effect is preferentially distributed to areas of maximal lung ventilation. It therefore may improve right ventricular function in acute pulmonary hypertension, and has therapeutic potential in acute respiratory failure associated with marked ventilation/perfusion inequality. 2 The use of inhaled NO in the management of severe respiratory failure and the adult respiratory syndrome (ARDS) in humans has recently been described. J We report the use of inhaled NO in two cases of severe respiratory failure associated with acute pulmonary hypertension and profound hypoxaemia. We describe aspects of the method of delivery and clinical management in intensive care. Informed consent from next of kin was obtained in both cases.
CASE REPORTS Case 1
A 67-year-old woman with a background of osteoarthritis, an inflammatory arthropathy regarded as seronegative rheumatoid arthritis, unexplained normocytic anaemia and a distant history of tuberculosis was referred for management of postoperative respiratory failure. An elective left total knee replacement was performed at another hospital under general anaesthesia, complicated 24 hours postoperatively by respiratory distress, fever and bilateral alveolar pulmonary infiltrates which required intubation and mechanical ventilation. There was no other significant history, and examination was remarkable for the lack of signs of an inflammatory synovitis. The initial working diagnosis was postoperative pneumonia secondary to aspiration, and she was managed with ventilation and intravenous antibiotics.
On the second day of admission she developed major haemoptysis with severe respiratory failure, which required high levels of PEEP (up to 12.5 cmH20) and ventilation with 100070 oxygen. The pulmonary artery wedge pressure was 17 mmHg and the cardiac index was estimated at 3.2 l.min-'.m-2 without inotropic support. Microbiological investigations were negative, the chest radiograph demonstrated progressive nodular and reticular shadowing and a serum antineutrophil cytoplasmic antibody level was estimated at 7 units. A fibreoptic bronchoscopy was not performed.
An open lung biopsy performed on the third day of admission demonstrated multiple areas of pulmonary haemorrhage associated with an acute alveolitis and vasculitis. The histopathological findings suggested a diagnosis of Wegener's granulomatosis or microscopic polyarteritis. Therapy with high dose intravenous methylprednisolone and plasmapheresis was instituted. On the advice of a clinical immunologist, cyclophosphamide was not given. Inhaled NO at a concentration of 40 ppm was commenced following the open lung biopsy when the Pa02 fell below 60 mmHg during ventilation with 100% oxygen. The immediate effects were a reduction in the mean pulmonary arterial pressure from 40 to 32 mmHg, and an increase in the arterial oxygen saturation. A reduction in shunt fraction and an increase in arterial P02 from 54 to 60 mmHg were observed after 1 hour (see Figure 1 ). The methaemoglobin level remained less than 2%. Despite maximal supportive therapy, which included inotropes, renal replacement therapy and empirical antibiotics, the patient succumbed to mUltiple organ failure and hypoxaemia on the sixth day of admission after three days of NO therapy.
Case 2
A thirty-year-old Aboriginal man was referred with acute severe respiratory failure on a background of heavy smoking, alcoholism and poor social circumstances. He had been admitted to his local hospital two days prior to his intensive care admission with radiographic evidence of left lower lobe pneumonia in association with a short history of cough productive of minimal sputum, fever, dyspnoea and left-side pleuritic chest pain. Broad-spectrum antibiotics were commenced after initial negative sputum microscopy; however, he deteriorated rapidly and was intubated and ventilated prior to transfer to our intensive care unit. Shortly after admission, a sputum culture from his local hospital grew Streptococcus pneumoniae, and his 60 50 -.... His course was one of rapid deterioration with severe respiratory failure marked reduction in lung compliance, bilateral alveolar infiltrates and hypoxaemia. The arterial P02 was 65 mmHg during ventilation with 100070 oxygen. The peak airway pressure was 48 cmH20 with tidal volumes of 900 ml, and the pulmonary capillary wedge pressure was 12 mmHg. These features were thought to represent ARDS secondary to acute bacterial pneumonia. During an infusion of adrenaline at 5 /-tg/min, the cardiac index (Cl) was 3.4 I.minl .m-2 , the systemic vascular resistance index 1477 dyn.sec.cm-5 .m 2 , the systemic oxygen delivery (D02) 468 ml.min-l .m-2 , and the systemic oxygen uptake (V02) 143 ml.min -1. m -2 calculated by the indirect Fick method. Fibreoptic bronchoscopy was performed on the third day of admission and recovered Enterobacter cloacae. Gramnegative antibiotic cover was added. The adrenaline infusion was weaned on the third day of admission. 
DELIVERY OF INHALED NITRIC OXIDE
NO is converted to higher oxides of nitrogen in the presence of oxygen. The major toxic product of this reaction is nitrogen dioxide (N02). Since patients with severe respiratory failure require high inspired oxygen concentrations, it is necessary to use a concentrated source of NO in nitrogen and dilute it immediately prior to use. We used a Siemens Servo 900C ventilator and cylinders containing 1000 or 2000 ppm NO in nitrogen. The cylinders were lined with Spectraseal ™ to prevent degradation of the stored NO. According to the manufacturer's specifications, the nitrogen carrier gas contained less than 2 ppm of oxygen and water, and less than 1 ppm of methane and carbon monoxide. The cylinder connectors and flow regulators were manufactured from stainless steel.
The delivery of NO was regulated by an Ecotech ™ electronic gas diluter/flowmeter (Ecotech model 8370). Gas was introduced, as a side stream, into the inspiratory limb of the ventilator tubing, allowing accumulation of gas within the circuit during expiration and minimising wastage. The NO source supplied contained less than 5070 higher oxides of nitrogen (information supplied by CIG), which would result in a concentration of less than 1 ppm N02 when delivered in its diluted form. The rate of conversion Contents Gauge ml.min-1 of NO to N02 is proportional to the oxygen concentration and the square of the concentration of NO. At a concentration of 10 ppm in oxygen, 50070 degradation occurs in 7 hours at room temperature, while at 10,000 ppm the same degree of degradation occurs in 24 seconds. 4 We assumed that, with constant flow, the concentration of N02 delivered to the patient would be insignificant, although direct measurement of N02 was not performed.
The mean concentration of NO delivered to the patient was estimated by setting the NO flowmeter to the desired fraction of the patient's minute volume. For example, if the desired concentration of NO is 20 ppm, and the source is 1000 ppm, a fiftyfold dilution is required. Therefore, if the inspired minute volume (Vi) is 10,000 mllmin, the desired flow rate is 10,000/50 = 200 mllmin. As a safety feature, an oxygen analyser was used to continuously monitor the inspired oxygen concentration at the catheter mount as nitrogen (the vehicle for NO) was being added upstream in the inspiratory limb. Exhaust ventilator gases were scavenged using a conventional anaesthetic scavenging system. Using this low-flow technique, one G-size cylinder should last for approximately 20 days. The delivery system is illustrated in Figure 3 .
We believe variable concentration of NO through the inspiratory period, although this was not monitored. Instead we estimated the mean concentration of NO throughout the respiratory cycle and correlated the flow rates of NO used with the therapeutic response. The effect of mixing and streaming within the circuit, endotracheal tube and patient's bronchial tree could not be ascertained.
DISCUSSION
These cases demonstrate the clinical use of inhaled NO in two patients with severe respiratory failure in an intensive care unit. The discovery of NO as an endogenous nitrovasodilator accounting for the activity of endothelium-derived relaxing factor (EDRF)5,6,7 has stimulated interest in many diverse areas of biological science. 8 NO is important in the regulation of vascular tone,5 acting locally by activating soluble guanylate cyclase and thereby producing smooth muscle relaxation. 9 Inhaled NO has been shown to be an effective and selective pulmonary vasodilator in both animal and human subjects with pulmonary hypertension. 1,10,11 The vasodilator effects of inhaled NO are highly specific for the pulmonary vasculature because the gas is inactivated rapidly as it enters the circulation, where it binds with high affinity to haemoglobin to produce methaemoglobin. Such specificity has never been achieved with systemic vasodilators.
Rossaint et al. 3 demonstrated that inhaled NO can reduce the intrapulmonary shunting, arterial hypoxaemia and pulmonary hypertension which characterise ARDS by producing selective vasodilatation in the maximally ventilated portions of the lungs without associated systemic effects. Their series of 10 patients with severe ARDS, largely due to direct lung injury, included 6 patients treated with extracorporeal membrane oxygenation. NO inhalation (18 or 36 ppm) produced significant falls in mean pulmonary artery pressure and intrapulmonary shunting. NO had no effect on cardiac output or systemic vascular resistance. In seven cases of long-term (3-53 days) NO inhalation (5-20 ppm) there was no evidence of tachyphylaxis and methaemoglobin levels remained less than 1.3%. Toxic effects from long-term use in animals have included methaemoglobinaemia, haemolytic anaemia and splenomegaly. 12 In the one human study to date, sl!ch effects were not observed. 3 Monitoring of inhaled concentrations of NO and N02 has been suggested for the clinical use of inhaled NO. 13 It is possible to measure the concentrations of these gases using chemiluminescent 14,15 or electrochemical techniques. It is claimed that the latter is an Anaesthesia and Intensive Care, Vol. 21, No. 6, December, 1993 easier technique to use. 16 This monitoring equipment was not available in these two emergency cases. In view of the potential toxicity of N02, such monitoring is likely to become mandatory for the routine clinical use of inhaled NO.
In the first case, therapy appeared less effective than in the second. This may reflect the different pathologies, case 1 having severe pulmonary vasculitis with diffuse alveolar haemorrhage, and case 2 manifesting classical ARDS. The presence of alveolar blood in the first case may have caused rapid inactivation of the inhaled NO. The second case demonstrated immediate and clinically significant improvements in intrapulmonary shunting, arterial hypoxaemia and pulmonary hypertension. Given the severity of the respiratory failure in this case, it seems likely that inhaled NO significantly influenced outcome. In both cases, no evidence of toxicity could be demonstrated. We conclude that the use of inhaled NO in severe respiratory failure requires further clinical investigation, but appears to be effective, particularly in ARDS.
In Australia, inhaled NO may be obtained for Category "A:' patients under the Special Access Scheme (SAS) arrangement for severely ill patients with a life-endangering illness.
Melbourne, since October 1992. Clinical use was preceded by work in the animal laboratory (unpublished). The method of administration is described in this issue of the journal. 6 At present, NO therapy is experimental in Australia and may only be used for patients in category A of the Special Access Scheme (SAS) of the Therapeutic Goods Administration. These patients must be terminally or seriously ill with life-threatening conditions and they or their guardians must give informed consent. Such consent was obtained from the parents of the children subject to report in this paper.
(A) TREATMENT OF PULMONARY HYPERTENSION AFTER CARDIAC SURGERY Case 1
This one-month-old infant had undergone surgical correction of total anomalous pulmonary venous drainage. The resting mean pulmonary artery pressure (PAP) on the first postoperative day was two-thirds of the mean systemic arterial pressure (SAP) and exceeded mean SAP transiently. The pulmonary hypertension was treated with intravenous glyceryl trinitrate (4 (tg/kg/min) and prostaglandin El (40 ng/kg/min), sedation and hypocarbia (P a C02 ::; 27 mmHg)
